Defunct Company
Total Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
200
NCT02239354
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 30, 2014
Completion: Dec 31, 2017
NCT02939118
One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™
Phase: N/A
Start: Nov 7, 2016
Completion: Feb 8, 2024
NCT03162926
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
Phase: Phase 1
Start: Jul 5, 2017
Completion: Feb 15, 2018
NCT03163511
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
Start: Jul 6, 2017
Completion: Oct 19, 2023
NCT04678557
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
Start: Jun 25, 2019
Completion: Nov 19, 2021
NCT05210530
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
Role: Collaborator
Start: Jan 24, 2022
Completion: Jan 19, 2023
NCT05565248
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
Start: Jan 20, 2023
Completion: Aug 31, 2025